Table III.
Functional and symptom outcomes derived from EORTC QLQ-C30 in the experimental and control groups 3 months after the intervention (mean ± SD).
| Groups
|
||||
|---|---|---|---|---|
| EORTC QLQ-C30 scales | Experimental | Control | t-value | P-value |
| Function | ||||
| Global | 78.6±24.7 | 58.1±22.3 | 3.018 | 0.002 |
| Physical | 83.8±24.9 | 64.2±21.5 | 2.913 | 0.003 |
| Role | 76.6±20.4 | 60.2±19.8 | 2.826 | 0.003 |
| Emotional | 64.5±21.8 | 50.6±18.6 | 2.376 | 0.011 |
| Cognitive | 75.6±34.3 | 76.7±28.0 | −0.122 | 0.452 |
| Social | 70.0±22.3 | 65.6±20.4 | 0.713 | 0.240 |
| Symptom | ||||
| Fatigue | 18.3±10.5 | 30.2±19.4 | −2.643 | 0.006 |
| Nausea/vomiting | 40.2±22.8 | 36.7±28.9 | 0.466 | 0.322 |
| Pain | 30.8±25.5 | 34.3±18.5 | −0.544 | 0.294 |
| Dyspnea | 35.6±14.1 | 41.4±20.2 | −1.153 | 0.127 |
| Insomnia | 37.2±15.0 | 36.9±10.8 | 0.0080 | 0.468 |
| Appetite loss | 4.2±4.7 | 12.1±11.4 | −3.139 | 0.001 |
| Constipation | 8.4±4.6 | 7.5±9.1 | 0.432 | 0.334 |
| Diarrhea | 22.0±8.5 | 25.6±9.2 | −1.408 | 0.083 |
| Financial difficulties | 12.4±10.9 | 14.7±12.6 | −0.676 | 0.251 |
EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 3.0; SD, standard deviation.